RMC No. 157-2022 updates the VAT-exempt medicines list under the CREATE Act, covering certain mental illness and COVID-19 treatment medicines.

Pharmacies, hospitals, clinics, drug distributors, and sellers of covered medicines must verify whether their products are included in the updated List of VAT-Exempt Medicines because the VAT exemption applies only from the date the Food and Drug Administration publishes the relevant updates. RMC No. 157-2022 matters immediately for businesses selling medicines prescribed for mental illness and COVID-19 treatment because the tax treatment of those products depends on the updated FDA-published list endorsed under the CREATE Act.

What RMC No. 157-2022 Changed

RMC No. 157-2022 publishes the November 28, 2022 letter of Food and Drug Administration Director General Samuel A. Zacate endorsing updates to the List of VAT-Exempt Medicines under Republic Act No. 11534, also known as the CREATE Act. The updated list now includes certain medicines prescribed for mental illness and COVID-19 treatment.

The practical effect is that taxpayers dealing with the covered medicines must treat the products as VAT-exempt only if they fall within the updated FDA-published List of VAT-Exempt Medicines. This is important because VAT exemption is product-specific. A medicine does not become VAT-exempt merely because it is health-related, prescribed by a physician, sold by a pharmacy, or used in a hospital setting. The controlling reference is whether the medicine is covered by the FDA-published updates recognized for purposes of the CREATE Act.

For CFOs, accountants, and tax managers, the key compliance issue is classification. The same business may sell both VATable and VAT-exempt products. If the accounting system, point-of-sale system, invoices, product master data, and tax codes are not updated, the taxpayer may either overcharge VAT on exempt medicines or fail to impose VAT on products that are not actually covered by the exemption.

Who Is Affected by the Updated VAT-Exempt Medicines List

RMC No. 157-2022 is most relevant to pharmaceutical retailers, drugstores, hospitals, clinics, health maintenance organizations, medicine distributors, importers, wholesalers, and corporate taxpayers that buy, sell, dispense, reimburse, or account for medicines prescribed for mental illness and COVID-19 treatment.

The circular also affects VAT-registered businesses with mixed transactions. A pharmacy, for example, may sell ordinary VATable goods, other VAT-exempt medicines, and medicines covered by the updated list. A hospital may bill patients for professional fees, room charges, medical supplies, and medicines with different tax treatments. A distributor may supply both covered and non-covered drugs to retail chains or healthcare institutions. In each case, the taxpayer must ensure that the VAT treatment follows the updated FDA list and not a generic product category description.

Corporate accountants and in-house counsel should also pay attention to the documentation trail. The relevant business records should show why a particular medicine was treated as VAT-exempt. This is especially important for taxpayers that may later need to explain the basis for VAT-exempt sales, reconcile sales reports, or support tax positions during BIR audit or internal compliance review.

Effective Date and Key Compliance Rule

The most important timing rule is that, as clarified in Q&A No. 1 of Revenue Memorandum Circular No. 99-2021, the effectivity of the VAT exemption of the covered medicines and medical devices under the CREATE Act takes effect on the date of publication by the FDA of the updates to the list.

This means that the relevant trigger is not simply the date of the FDA endorsement letter, not merely the date of internal company awareness, and not merely the date a seller updates its system. The operative rule stated in the circular is tied to the FDA publication of the updates to the List of VAT-Exempt Medicines.

RMC No. 157-2022 was issued on December 27, 2022, and it publishes the FDA Director General’s November 28, 2022 endorsement of updates. Businesses should therefore review their transaction dates against the FDA publication date of the relevant list update before applying VAT-exempt treatment. This is particularly important when determining whether sales made before and after the update should be treated differently.

What Businesses Must Do Now

Businesses selling medicines should first identify whether any of their products are medicines prescribed for mental illness or COVID-19 treatment that appear in the updated FDA-published List of VAT-Exempt Medicines. Product names, registration details, inventory codes, and medicine categories should be reviewed carefully because the exemption is not a blanket exemption for all medicines related to mental health or COVID-19.

Second, accounting and tax teams should update their VAT coding. Covered medicines should be mapped to the appropriate VAT-exempt tax code only from the applicable effective date. Non-covered medicines should remain under their correct tax treatment. For businesses with point-of-sale systems, the product master list should be checked to avoid inconsistent VAT treatment across branches, online stores, hospital pharmacies, and distributor invoicing systems.

Third, finance teams should review invoices, official receipts, sales reports, and VAT returns for the affected period. If a business charged VAT on a product that should have been treated as VAT-exempt after the applicable FDA publication date, management should assess the proper corrective treatment. If a business failed to impose VAT on a product not actually covered by the updated list, it should immediately review its exposure and correct the classification prospectively.

Fourth, procurement and reimbursement teams should coordinate with suppliers. Buyers of covered medicines may need to confirm whether suppliers are applying VAT-exempt treatment consistently. This is especially relevant for hospitals, clinics, and corporate health programs that depend on supplier invoices for accounting, patient billing, or internal reimbursements.

Penalties and Audit Risk for Incorrect VAT Treatment

RMC No. 157-2022 does not state a special penalty for non-compliance. However, incorrect VAT classification can still create BIR audit risk under the ordinary rules applicable to VAT reporting, invoicing, and tax return preparation. The main risk is not merely whether a product is medical in nature, but whether the taxpayer can substantiate that the product was included in the FDA-published List of VAT-Exempt Medicines and that the exemption was applied only from the proper effective date.

Businesses should avoid vague descriptions such as “medical supplies,” “COVID medicine,” or “mental health medicine” as the sole basis for VAT exemption. Internal tax files should identify the covered medicine and connect it to the updated list. A clear compliance trail is especially important for VAT-registered taxpayers with mixed sales, because errors in classification can affect sales reporting, invoice issuance, and management’s evaluation of VAT exposure.

Search Phrases Taxpayers Use for This Issuance

Taxpayers commonly search for this issuance using phrases such as RMC No. 157-2022 VAT-exempt medicines, CREATE Act VAT exemption medicines, FDA list of VAT-exempt medicines Philippines, VAT-exempt COVID-19 medicines Philippines, and VAT exemption medicines for mental illness. These phrases all point to the same practical issue: whether a particular medicine may be sold without VAT, and when the exemption becomes effective.

How Ablola, Saribong & Gueco Can Help

Ablola, Saribong & Gueco assists businesses in reviewing BIR issuances, implementing VAT compliance procedures, updating tax documentation, and preparing defensible positions for BIR audits. For pharmaceutical companies, hospitals, clinics, drugstores, distributors, and other taxpayers affected by RMC No. 157-2022, the firm can help assess whether products are covered by the updated VAT-exempt medicines list, align invoicing and accounting treatment, and prepare compliance documentation.

For assistance with VAT compliance, BIR audit preparation, tax classification of medicines, or implementation of CREATE Act tax exemptions, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.


Leave a Comment

Your email address will not be published. Required fields are marked *